Arcturus Therapeutics Files 8-K
Ticker: ARCT · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1768224
| Field | Detail |
|---|---|
| Company | Arcturus Therapeutics Holdings Inc. (ARCT) |
| Form Type | 8-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, financials
Related Tickers: ARCT
TL;DR
ARCT filed a standard 8-K on 6/30/25, no major news.
AI Summary
Arcturus Therapeutics Holdings Inc. filed an 8-K on June 30, 2025, reporting on financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for the period ending June 30, 2025. The company is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing serves as a routine update for investors, confirming the company's adherence to reporting standards without disclosing new material information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, indicating no new material events or risks.
Key Players & Entities
- Arcturus Therapeutics Holdings Inc. (company) — Registrant
- June 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
- 10628 Science Center Drive, Suite 250 (address) — Business address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of June 30, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is June 30, 2025.
In which state is Arcturus Therapeutics Holdings Inc. incorporated?
Arcturus Therapeutics Holdings Inc. is incorporated in Delaware.
What is the principal executive office address for Arcturus Therapeutics Holdings Inc.?
The principal executive office address is 10628 Science Center Drive, Suite 250, San Diego, California 92121.
Does this filing disclose any new material events or financial results?
Based on the provided text, this filing appears to be a routine report of financial statements and exhibits, and does not explicitly disclose new material events or specific financial results beyond the reporting period.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Arcturus Therapeutics Holdings Inc. (ARCT).